Biological features of thoracic aortic diseases. Where are we now, where are we heading to: Established and emerging biomarkers and molecular pathways

European Journal of Cardio-thoracic Surgery

Volumn 44, Issue 1, 2013, Pages 9-23

  Parolari, Alessandro ^a,b   Tremoli, Elena ^a,b   Songia, Paola ^b   Pilozzi, Alberto ^a   Di Bartolomeo, Roberto ^c   Alamanni, Francesco ^a,b   Mestres, Carlos A ^d   Pacini, Davide ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b CENTRO CARDIOLOGICO MONZINO   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Aneurysm; Aorta; Aortic diseases; Biomarkers; Dissection; Thoracic aorta

Indexed keywords

ALPHA ACTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN I; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CALPONIN; COLLAGEN TYPE 3; D DIMER; FIBRILLIN 1; FIBULIN 5; FILAMIN A; GELATINASE A; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MENADIONE EPOXIDE; MYOSIN HEAVY CHAIN BETA; MYOSIN LIGHT CHAIN KINASE; NEUTROPHIL COLLAGENASE; NOTCH1 RECEPTOR; OSTEOPONTIN; STROMELYSIN; THROMBOSPONDIN 2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TROPONIN;

AORTA ANEURYSM; AORTA DISEASE; AORTA DISSECTION; ARTICLE; CELL DAMAGE; EXTRACELLULAR MATRIX; GENE MUTATION; GENETIC MARKER; GENETICS; HEMOSTASIS; HUMAN; INFLAMMATION; OXIDATIVE STRESS; PRIORITY JOURNAL; THORAX DISEASE;

ANEURYSM; AORTA; AORTIC DISEASES; BIOMARKERS; DISSECTION; THORACIC AORTA;

ANEURYSM, DISSECTING; AORTA, THORACIC; AORTIC ANEURYSM, THORACIC; BIOLOGICAL MARKERS; HUMANS;

EID: 84879592502     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezs647     Document Type: Article

References (140)

1. Clouse WD, Hallett JW Jr, Schaff HV, Gayari MM, Ilstrup DM, Melton LJ III. Improved prognosis of thoracic aortic aneurysms: a populationbased study. JAMA 1998;280:1926-9.
2. Clouse WD, Hallett JW Jr, Schaff HV, Spittell PC, Rowland CM, Ilstrup DM et al. Acute aortic dissection: population-192based incidence compared with degenerative aortic aneurysm rupture. Mayo Clin Proc 2004;79:176-80.
3. Meszaros I, Morocz J, Szlavi J, Schmidt J, Tornoci L, Nagy L et al. Epidemiology and clinicopathology of aortic dissection. Chest 2000; 117:1271-8.
4. Albornoz G, Coady MA, Roberts M, Davies RR, Tranquilli M, Rizzo JA et al. Familial thoracic aortic aneurysms and dissections-incidence, modes of inheritance, and phenotypic patterns. Ann Thorac Surg 2006; 82:1400-5.
5. Booher AM, Eagle KA. Diagnosis and management issues in thoracic aortic aneurysm. Am Heart J 2011;162:38-46, e1.
6. Pollack A. A Blood Test Offers Clues to Longevity. The New York Times [published 18 May 2011]. Available from: http://www.nytimes.com/ 2011/05/19/business/19life.html?pagewanted=all&_r=0.
7. Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 1991;352:337-9.
8. Goumans MJ, Liu Z, ten Dijke P. TGF-1beta signaling in vascular biology and dysfunction. Cell Res 2009;19:116-27.
9. Laiho M, Saksela O, Keski-1Oja J. Transforming growth factor beta alters plasminogen activator activity in human skin fibroblasts. Exp Cell Res 1986;164:399-407.
10. Laiho M, Saksela O, Andreasen PA, Keski-Oja J. Enhanced production and extracellular deposition of the endothelial-type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-beta. J Cell Biol 1986;103:2403-10.
11. Xiong W, Meisinger T, Knispel R, Worth JM, Baxter BT. MMP-242 regulates Erk1/2 phosphorylation and aortic dilatation in Marfan syndrome. Circ Res 2012;110:e92-e101.
12. Isogai Z, Ono RN, Ushiro S, Keene DR, Chen Y, Mazzieri R et al. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem 2003;278: 2750-7.
13. Loeys BL, Schwarze U, Holm T, Callewaert BL, Thomas GH, Pannu H et al. Aneurysm syndromes caused by mutations in the TGF-275beta receptor. N Engl J Med 2006;355:788-98.
14. Lemaire SA, McDonald ML, Guo DC, Russell L, Miller CC 3rd, Johnson RJ et al. Genome-7wide association study identifies a susceptibility locus for thoracic aortic aneurysms and aortic dissections spanning FBN1 at 15q21.1. Nat Genet 2011;43:996-1000.
15. Harrison SC, Holmes MV, Agu O, Humphries SE. Genome wide association studies of abdominal aortic aneurysms-biological insights and potential translation applications. Atherosclerosis 2011;217: 47-56.
16. Carta L, Pereira L, Arteaga-Solis E, Lee-Arteaga SY, Lenart B, Starcher B et al. Fibrillins 1 and 2 perform partially overlapping functions during aortic development. J Biol Chem 2006;281:8016-23.
17. McKellar SH, Tester DJ, Yagubyan M, Majumdar R, Ackerman MJ, Sundt TM 3rd. Novel NOTCH1 mutations in patients with bicuspid aortic valve disease and thoracic aortic aneurysms. J Thorac Cardiovasc Surg 2007;134:290-6.
18. Hucthagowder V, Sausgruber N, Kim KH, Angle B, Marmorstein LY, Urban Z. Fibulin-804: a novel gene for an autosomal recessive cutis laxa syndrome. Am J Hum Genet 2006;78:1075-80.
19. Al-10Hassnan ZN, Almesned AR, Tulbah S, Hakami A, Al-Omrani A, Al Sehly A et al. Recessively inherited severe aortic aneurysm caused by mutated EFEMP2. Am J Cardiol 2012;109:1677-80.
20. Loeys B, Van Maldergem L, Mortier G, Coucke P, Gerniers S, Naeyaert JM et al. Homozygosity for a missense mutation in fibulin-165 (FBLN5) results in a severe form of cutis laxa. Hum Mol Genet 2002;11: 2113-8.
21. Wang X, LeMaire SA, Chen L, Carter SA, Shen YH, Gan Y et al. Decreased expression of fibulin-2115 correlates with reduced elastin in thoracic aortic dissection. Surgery 2005;138:352-9.
22. Kato K, Oguri M, Kato N, Hibino T, Yajima K, Yoshida T et al. Assessment of genetic risk factors for thoracic aortic aneurysm in hypertensive patients. Am J Hypertens 2008;21:1023-7.
23. Sheen VL, Jansen A, Chen MH, Parrini E, Morgan T, Ravenscroft R et al. Filamin A mutations cause periventricular heterotopia with Ehlers-3Danlos syndrome. Neurology 2005;64:254-62.
24. Pilop C, Aregger F, Gorman RC, Brunisholz R, Gerrits B, Schaffner T et al. Proteomic analysis in aortic media of patients with Marfan syndrome reveals increased activity of calpain 2 in aortic aneurysms. Circulation 2009;120:983-91.
25. Wang L, Guo DC, Cao J, Gong L, Kamm KE, Regalado E et al. Mutations in myosin light chain kinase cause familial aortic dissections. Am J Hum Genet 2010;87:701-7.
26. van de Laar IM, Oldenburg RA, Pals G, Roos-2Hesselink JW, de Graaf BMVerhagen JM et al. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet 2011;43:121-6.
27. Regalado ES, Guo DC, Villamizar C, Avidan N, Gilchrist D, McGillivray B et al. Exome sequencing identifies SMAD3 mutations as a cause of familial thoracic aortic aneurysm and dissection with intracranial and other arterial aneurysms. Circ Res 2011;109:680-6.
28. van de Laar IM, van der Linde D, Oei EH, Bos PK, Bessems JH, Bierma-12Zeinstra SM et al. Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome. J Med Genet 2012;49:47-57.
29. Gomez D, Coyet A, Ollivier V, Jeunemaitre X, Jondeau G, Michel JB et al. Epigenetic control of vascular smooth muscle cells in Marfan and non-Marfan thoracic aortic aneurysms. Cardiovasc Res 2011;89:446-56.
30. Rodrigues Diez R, Rodrigues-4Diez R, Lavoz C, Rayego-Mateos S, Civantos E, Rodriguez-Vita J et al. Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF-beta-independent process. PLoS ONE 2010;5:e14145.
31. Kalay N, Caglayan O, Akkaya H, Ozdogru I, Dogan A, Inanc MT et al. The deletion polymorphism of the angiotensin-converting enzymegene is associated with acute aortic dissection. Tohoku J Exp Med 2009;219:33-7.
32. Wang Y, Zhang W, Zhang Y, Yang Y, Sun L, Hu S et al. VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection). Circulation 2006;113:1615-21.
33. Eggebrecht H, Naber CK, Bruch C, Kroger K, von Birgelen C, Schmermund A et al. Value of plasma fibrin D-3dimers for detection of acute aortic dissection. J Am Coll Cardiol 2004;44:804-9.
34. Makita S, Ohira A, Tachieda R, Itoh S, Moriai Y, Yoshioka K et al. Behavior of C-80reactive protein levels in medically treated aortic dissection and intramural hematoma. Am J Cardiol 2000;86:242-4.
35. Schillinger M, Domanovits H, Bayegan K, Holzenbein T, Grabenwoger M Thoenissen J et al. C-24reactive protein and mortality in patients with acute aortic disease. Intensive Care Med 2002;28:740-5.
36. Wen D, Zhou XL, Li JJ, Luo F, Zhang L, Gao LG et al. Plasma concentrations of interleukin-746, C-reactive protein, tumor necrosis factor-alpha and matrix metalloproteinase-9 in aortic dissection. Clin Chim Acta 2012;413:198-202.
37. Yuan SM, Shi YH, Wang JJ, Lu FQ, Gao S. Elevated plasma D-dimer and hypersensitive C-reactive protein levels may indicate aortic disorders. Rev Bras Cir Cardiovasc 2011;26:573-81.
38. Sbarouni E, Georgiadou P, Marathias A, Geroulanos S, Kremastinos DT. D-dimer and BNP levels in acute aortic dissection. Int J Cardiol 2007; 122:170-2.
39. Wen D, Wu HY, Jiang XJ, Zhang HM, Zhou XL, Li JJ et al. Role of plasma C-reactive protein and white blood cell count in predicting in-hospital clinical events of acute type A aortic dissection. Chin Med J (Engl) 2011;124:2678-82.
40. Sakakura K, Kubo N, Ako J, Wada H, Fujiwara N, Funayama H et al. Peak C-reactive protein level predicts long-term outcomes in type B acute aortic dissection. Hypertension 2010;55:422-9.
41. Ihara A, Matsumoto K, Kawamoto T, Shouno S, Kawamoto J, Katayama A et al. Relationship between hemostatic markers and platelet indices in patients with aortic aneurysm. Pathophysiol Haemost Thromb 2006; 35:451-6.
42. Nomura F, Ihara A, Yoshitatsu M, Tamura K, Katayama A, Ihara K. Relationship between coagulation cascade, cytokine, adhesion molecule and aortic aneurysm. Eur J Cardiothorac Surg 2003;23:1034-8; discussion 8-9.
43. Fiorillo C, Becatti M, Attanasio M, Lucarini L, Nassi N, Evangelisti L et al. Evidence for oxidative stress in plasma of patients with Marfan syndrome. Int J Cardiol 2010;145:544-6.
44. Ejiri J, Inoue N, Tsukube T, Munezane T, Hino Y, Kobayashi S et al. Oxidative stress in the pathogenesis of thoracic aortic aneurysm: protective role of statin and angiotensin II type 1 receptor blocker. Cardiovasc Res 2003;59:988-96.
45. Liao M, Liu Z, Bao J, Zhao Z, Hu J, Feng X et al. A proteomic study of the aortic media in human thoracic aortic dissection: implication for oxidative stress. J Thorac Cardiovasc Surg 2008;136:65-72, e1-3.
46. Weber T, Hogler S, Auer J, Berent R, Lassnig E, Kvas E et al. D-dimer in acute aortic dissection. Chest 2003;123:1375-8.
47. Perez A, Abbet P, Drescher MJ. D-dimers in the emergency department evaluation of aortic dissection. Acad Emerg Med 2004;11: 397-400.
48. Akutsu K, Sato N, Yamamoto T, Morita N, Takagi H, Fujita N et al. A rapid bedside D-dimer assay (cardiac D-dimer) for screening of clinically suspected acute aortic dissection. Circ J 2005;69:397-403.
49. Ohlmann P, Morel O, Radulescu B, Kindo M, Faure A, Billaud P et al. D-Dimer in ruling out acute aortic dissection: sensitivity is not 100%. Eur Heart J 2008;29:828-9; author reply 9.
50. Sodeck G, Domanovits H, Schillinger M, Ehrlich MP, Endler G, Herkner H et al. D-dimer in ruling out acute aortic dissection: a systematic review and prospective cohort study. Eur Heart J 2007;28:3067-75.
51. Suzuki T, Distante A, Zizza A, Trimarchi S, Villani M, Salerno Uriarte JA et al. Diagnosis of acute aortic dissection by D-dimer: the International Registry of Acute Aortic Dissection Substudy on Biomarkers (IRAD-Bio) experience. Circulation 2009;119:2702-7.
52. Paparella D, Malvindi PG, Scrascia G, de Ceglia D, Rotunno C, Tunzi F et al. D-dimers are not always elevated in patients with acute aortic dissection. J Cardiovasc Med (Hagerstown) 2009;10:212-4.
53. Ohlmann P, Faure A, Morel O, Kindo M, Jesel L, Radulescu B et al. Lower circulating Sta-Liatest D-Di levels in patients with aortic intramural hematoma compared with classical aortic dissection. Crit Care Med 2009;37:899-901.
54. Hazui H, Nishimoto M, Hoshiga M, Negoro N, Muraoka H, Murai M et al. Young adult patients with short dissection length and thrombosed false lumen without ulcer-like projections are liable to have false-negative results of D-dimer testing for acute aortic dissection based on a study of 113 cases. Circ J 2006;70:1598-601.
55. Hazui H, Fukumoto H, Negoro N, Hoshiga M, Muraoka H, Nishimoto M et al. Simple and useful tests for discriminating between acute aortic dissection of the ascending aorta and acute myocardial infarction in the emergency setting. Circ J 2005;69:677-82.
56. Nagaoka K, Sadamatsu K, Yamawaki T, Shikada T, Sagara S, Ohe K et al. Fibrinogen/fibrin degradation products in acute aortic dissection. Intern Med 2010;49:1943-7.
57. Iyano K, Kawada T, Aiba M, Takaba T. Correlation of hemostatic molecular markers and morphology of the residual false lumen in chronic aortic dissection. Ann Thorac Cardiovasc Surg 2004;10:106-12.
58. Jo Y, Anzai T, Ueno K, Kaneko H, Kohno T, Sugano Y et al. Re-elevation of D-dimer as a predictor of re-dissection and venous thromboembolism after Stanford type B acute aortic dissection. Heart Vessels 2010;25: 509-14.
59. Shimony A, Filion KB, Mottillo S, Dourian T, Eisenberg MJ. Meta-analysis of usefulness of d-dimer to diagnose acute aortic dissection. Am J Cardiol 2011;107:1227-34.
60. Nomura F, Tamura K, Yoshitatsu M, Katayama A, Katayama K, Ihara K. Changes in coagulation condition, cytokine, adhesion molecule after repair of type A aortic dissection. Eur J Cardiothorac Surg 2004;26: 348-50.
61. del Porto F, Proietta M, Tritapepe L, Miraldi F, Koverech A, Cardelli P et al. Inflammation and immune response in acute aortic dissection. Ann Med 2010;42:622-9.
62. Gallo A, Saad A, Ali R, Dardik A, Tellides G, Geirsson A. Circulating interferon-gamma-inducible Cys-X-Cys chemokine receptor 3 ligands are elevated in humans with aortic aneurysms and Cys-X-Cys chemokine receptor 3 is necessary for aneurysm formation in mice. J Thorac Cardiovasc Surg 2012;143:704-10.
63. Zhang L, Liao MF, Tian L, Zou SL, Lu QS, Bao JM et al. Overexpression of interleukin-1beta and interferon-gamma in type I thoracic aortic dissections and ascending thoracic aortic aneurysms: possible correlation with matrix metalloproteinase-9 expression and apoptosis of aortic media cells. Eur J Cardiothorac Surg 2011;40:17-22.
64. Tang PC, Yakimov AO, Teesdale MA, Coady MA, Dardik A, Elefteriades JA et al. Transmural inflammation by interferon-gammaproducing T cells correlates with outward vascular remodeling and intimal expansion of ascending thoracic aortic aneurysms. FASEB J 2005;19:1528-30.
65. He R, Guo DC, Estrera AL, Safi HJ, Huynh TT, Yin Z et al. Characterization of the inflammatory and apoptotic cells in the aortas of patients with ascending thoracic aortic aneurysms and dissections. J Thorac Cardiovasc Surg 2006;131:671-8.
66. Paparella D, Rotunno C, Guida P, Malvindi PG, Scrascia G, De Palo M et al. Hemostasis alterations in patients with acute aortic dissection. Ann Thorac Surg 2011;91:1364-9.
67. Clark JM, Glagov S. Transmural organization of the arterial media. The lamellar unit revisited. Arteriosclerosis 1985;5:19-34.
68. Dingemans KP, Teeling P, Lagendijk JH, Becker AE. Extracellular matrix of the human aortic media: an ultrastructural histochemical and immunohistochemical study of the adult aortic media. Anat Rec 2000;258: 1-14.
69. Virmani R, Avolio AP, Mergner WJ, Robinowitz M, Herderick EE, Cornhill JF et al. Effect of aging on aortic morphology in populations with high and low prevalence of hypertension and atherosclerosis. Comparison between occidental and Chinese communities. Am J Pathol 1991;139:1119-29.
70. Spina M, Garbisa S, Hinnie J, Hunter JC, Serafini-Fracassini A. Age-related changes in composition and mechanical properties of the tunica media of the upper thoracic human aorta. Arteriosclerosis 1983; 3:64-76.
71. Powell JT, Vine N, Crossman M. On the accumulation of D-aspartate in elastin and other proteins of the ageing aorta. Atherosclerosis 1992;97: 201-8.
72. Rucker RB, Tinker D. Structure and metabolism of arterial elastin. Int Rev Exp Pathol 1977;17:1-47.
73. Shinohara T, Suzuki K, Okada M, Shiigai M, Shimizu M, Maehara T et al. Soluble elastin fragments in serum are elevated in acute aortic dissection. Arterioscler Thromb Vasc Biol 2003;23:1839-44.
74. Theruvath TP, Jones JA, Ikonomidis JS. Matrix metalloproteinases and descending aortic aneurysms: parity, disparity, and switch. J Card Surg 2012;27:81-90.
75. Zhang X, Shen YH, LeMaire SA. Thoracic aortic dissection: are matrix metalloproteinases involved? Vascular 2009;17:147-57.
76. Koullias GJ, Ravichandran P, Korkolis DP, Rimm DL, Elefteriades JA. Increased tissue microarray matrix metalloproteinase expression favors proteolysis in thoracic aortic aneurysms and dissections. Ann Thorac Surg 2004;78:2106-10; discussion 10-1.
77. Schmoker JD, McPartland KJ, Fellinger EK, Boyum J, Trombley L, Ittleman FP et al. Matrix metalloproteinase and tissue inhibitor expression in atherosclerotic and nonatherosclerotic thoracic aortic aneurysms. J Thorac Cardiovasc Surg 2007;133:155-61.
78. Boyum J, Fellinger EK, Schmoker JD, Trombley L, McPartland K, Ittleman FP et al. Matrix metalloproteinase activity in thoracic aortic aneurysms associated with bicuspid and tricuspid aortic valves. J Thorac Cardiovasc Surg 2004;127:686-91.
79. Ikonomidis JS, Jones JA, Barbour JR, Stroud RE, Clark LL, Kaplan BS et al. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome. Circulation 2006;114:I365-70.
80. Sinha I, Bethi S, Cronin P, Williams DM, Roelofs K, Ailawadi G et al. A biologic basis for asymmetric growth in descending thoracic aortic aneurysms: a role for matrix metalloproteinase 9 and 2. J Vasc Surg 2006;43:342-8.
81. Borges LF, Touat Z, Leclercq A, Zen AA, Jondeau G, Franc B et al. Tissue diffusion and retention of metalloproteinases in ascending aortic aneurysms and dissections. Hum Pathol 2009;40:306-13.
82. Sangiorgi G, Trimarchi S, Mauriello A, Righini P, Bossone E, Suzuki T et al. Plasma levels of metalloproteinases-9 and -2 in the acute and subacute phases of type A and type B aortic dissection. J Cardiovasc Med (Hagerstown) 2006;7:307-15.
83. Monaco M, Stassano P, Di Tommaso L, Iannelli G. Response of plasma matrix metalloproteinases and tissue inhibitor of metalloproteinases to stent-graft surgery for descending thoracic aortic aneurysms. J Thorac Cardiovasc Surg 2007;134:925-31.
84. Karapanagiotidis GT, Antonitsis P, Charokopos N, Foroulis CN, Anastasiadis K, Rouska E et al. Serum levels of matrix metalloproteinases -1,-2,-3 and -9 in thoracic aortic diseases and acute myocardial ischemia. J Cardiothorac Surg 2009;4:59.
85. Didangelos A, Yin X, Mandal K, Baumert M, Jahangiri M, Mayr M. Proteomics characterization of extracellular space components in the human aorta. Mol Cell Proteomics 2010;9:2048-62.
86. Li Y, Shao AZ, Jiang HT, Dong GH, Xu B, Yi J et al. The prominent expression of plasma matrix metalloproteinase-8 in acute thoracic aortic dissection. J Surg Res 2010;163:e99-104.
87. Levula M, Paavonen T, Valo T, Pelto-Huikko M, Laaksonen R, Kahonen M et al. A disintegrin and metalloprotease -8 and -15 and susceptibility for ascending aortic dissection. Scand J Clin Lab Invest 2011;71: 515-22.
88. Huusko T, Salonurmi T, Taskinen P, Liinamaa J, Juvonen T, Paakko P et al. Elevated messenger RNA expression and plasma protein levels of osteopontin and matrix metalloproteinase types 2 and 9 in patients with ascending aortic aneurysms. J Thorac Cardiovasc Surg; 10.1016/j. jtcvs.2012.04.008.
89. Grau JB, Poggio P, Sainger R, Vernick WJ, Seefried WF, Branchetti E et al. Analysis of osteopontin levels for the identification of asymptomatic patients with calcific aortic valve disease. Ann Thorac Surg 2012;93: 79-86.
90. Parolari A, Loardi C, Mussoni L, Cavallotti L, Camera M, Biglioli P et al. Nonrheumatic calcific aortic stenosis: an overview from basic science to pharmacological prevention. Eur J Cardiothorac Surg 2009;35: 493-504.
91. Lesauskaite V, Tanganelli P, Sassi C, Neri E, Diciolla F, Ivanoviene L et al. Smooth muscle cells of the media in the dilatative pathology of ascending thoracic aorta: morphology, immunoreactivity for osteopontin, matrix metalloproteinases, and their inhibitors. Hum Pathol 2001; 32:1003-11.
92. Gao H, Steffen MC, Ramos KS. Osteopontin regulates alpha-smooth muscle actin and calponin in vascular smooth muscle cells. Cell Biol Int 2012;36:155-61.
93. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525-38.
94. Bonnefoy E, Godon P, Kirkorian G, Chabaud S, Touboul P. Significance of serum troponin I elevation in patients with acute aortic dissection of the ascending aorta. Acta Cardiol 2005;60:165-70.
95. Hansen MS, Nogareda GJ, Hutchison SJ. Frequency of and inappropriate treatment of misdiagnosis of acute aortic dissection. Am J Cardiol 2007;99:852-6.
96. Ohlmann P, Faure A, Morel O, Petit H, Kabbaj H, Meyer N et al. Diagnostic and prognostic value of circulating D-Dimers in patients with acute aortic dissection. Crit Care Med 2006;34:1358-64.
97. Rapezzi C, Longhi S, Graziosi M, Biagini E, Terzi F, Cooke RM et al. Risk factors for diagnostic delay in acute aortic dissection. Am J Cardiol 2008;102:1399-406.
98. Davidson E, Weinberger I, Rotenberg Z, Fuchs J, Maler S, Agmon J. Elevated serum creatine kinase levels. An early diagnostic sign of acute dissection of the aorta. Arch Intern Med 1988;148:2184-6.
99. Suzuki T, Katoh H, Kurabayashi M, Yazaki Y, Nagai R. Biochemical diagnosis of aortic dissection by raised concentrations of creatine kinase BB-isozyme. Lancet 1997;350:784-5.
100. Suzuki T, Katoh H, Watanabe M, Kurabayashi M, Hiramori K, Hori S et al. Novel biochemical diagnostic method for aortic dissection. Results of a prospective study using an immunoassay of smooth muscle myosin heavy chain. Circulation 1996;93:1244-9.
101. Suzuki T, Katoh H, Tsuchio Y, Hasegawa A, Kurabayashi M, Ohira A et al. Diagnostic implications of elevated levels of smooth-muscle myosin heavy-chain protein in acute aortic dissection. The smooth muscle myosin heavy chain study. Ann Intern Med 2000;133:537-41.
102. Suzuki T, Distante A, Zizza A, Trimarchi S, Villani M, Salerno Uriarte JA et al. Preliminary experience with the smooth muscle troponin-like protein, calponin, as a novel biomarker for diagnosing acute aortic dissection. Eur Heart J 2008;29:1439-5.
103. Sodeck G, Domanovits H, Schillinger M, Janata K, Thalmann M, Ehrlich MP et al. Pre-operative N-terminal pro-brain natriuretic peptide predicts outcome in type A aortic dissection. J Am Coll Cardiol 2008;51:1092-7.
104. Wang Y, Barbacioru CC, Shiffman D, Balasubramanian S, Iakoubova O, Tranquilli M et al. Gene expression signature in peripheral blood detects thoracic aortic aneurysm. PLoS ONE 2007;2:e1050.
105. Liao M, Zou S, Weng J, Hou L, Yang L, Zhao Z et al. A microRNA profile comparison between thoracic aortic dissection and normal thoracic aorta indicates the potential role of microRNAs in contributing to thoracic aortic dissection pathogenesis. J Vasc Surg 2011;53:1341-9 e3.
106. Merk DR, Chin JT, Dake BA, Maegdefessel L, Miller MO, Kimura N et al. miR-29b participates in early aneurysm development in Marfan syndrome. Circ Res 2012;110:312-24.
107. Zampetaki A, Willeit P, Tilling L, Drozdov I, Prokopi M, Renard JM et al. Prospective study on circulating microRNAs and risk of myocardial infarction. J Am Coll Cardiol 2012;60:290-9.
108. Hope MD, Wrenn J, Sigovan M, Foster E, Tseng EE, Saloner D. Imaging biomarkers of aortic disease: increased growth rates with eccentric systolic flow. J Am Coll Cardiol 2012;60:356-7.
109. Superti-Furga A, Gugler E, Gitzelmann R, Steinmann B. Ehlers-Danlos syndrome type IV: a multi-exon deletion in one of the two COL3A1 alleles affecting structure, stability, and processing of type III procollagen. J Biol Chem 1988;263:6226-32.
110. Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med 2000;342:673-80.
111. Ades LC, Sreetharan D, Onikul E, Stockton V, Watson KC, Holman KJ. Segregation of a novel FBN1 gene mutation, G1796E, with kyphoscoliosis and radiographic evidence of vertebral dysplasia in three generations. Am J Med Genet 2002;109:261-70.
112. Francke U, Berg MA, Tynan K, Brenn T, Liu W, Aoyama T et al. A Gly1127Ser mutation in an EGF-like domain of the fibrillin-1 gene is a risk factor for ascending aortic aneurysm and dissection. Am J Hum Genet 1995;56:1287-96.
113. Katzke S, Booms P, Tiecke F, Palz M, Pletschacher A, Turkmen S et al. TGGE screening of the entire FBN1 coding sequence in 126 individuals with marfan syndrome and related fibrillinopathies. Hum Mutat 2002;20:197-208.
114. Milewicz DM, Grossfield J, Cao SN, Kielty C, Covitz W, Jewett T. A mutation in FBN1 disrupts profibrillin processing and results in isolated skeletal features of the Marfan syndrome. J Clin Invest 1995;95:2373-8.
115. Milewicz DM, Michael K, Fisher N, Coselli JS, Markello T, Biddinger A. Fibrillin-1 (FBN1) mutations in patients with thoracic aortic aneurysms. Circulation 1996;94:2708-11.
116. High FA, Epstein JA. The multifaceted role of Notch in cardiac development and disease. Nat Rev Genet 2008;9:49-61.
117. Garg V, Muth AN, Ransom JF, Schluterman MK, Barnes R, King IN et al. Mutations in NOTCH1 cause aortic valve disease. Nature 2005;437: 270-4.
118. Coucke PJ, Willaert A, Wessels MW, Callewaert B, Zoppi N, De Backer J et al. Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome. Nat Genet 2006; 38:452-7.
119. Callewaert BL, Willaert A, Kerstjens-Frederikse WS, De Backer J, Devriendt K, Albrecht B et al. Arterial tortuosity syndrome: clinical and molecular findings in 12 newly identified families. Hum Mutat 2008;29: 150-8.
120. Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 2005;37:275-81.
121. Collod G, Babron MC, Jondeau G, Coulon M, Weissenbach J, Dubourg O et al. A second locus for Marfan syndrome maps to chromosome 3p24.2-p25. Nat Genet 1994;8:264-8.
122. Mizuguchi T, Collod-Beroud G, Akiyama T, Abifadel M, Harada N, Morisaki T et al. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet 2004;36:855-60.
123. Guo DC, Pannu H, Tran-Fadulu V, Papke CL, Yu RK, Avidan N et al. Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat Genet 2007;39:1488-93.
124. Zhu L, Vranckx R, Khau Van Kien P, Lalande A, Boisset N, Mathieu F et al. Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat Genet 2006;38:343-9.
125. Khau Van Kien P, Mathieu F, Zhu L, Lalande A, Betard C, Lathrop M et al. Mapping of familial thoracic aortic aneurysm/dissection with patent ductus arteriosus to 16p12.2-p13.13. Circulation 2005;112: 200-6.
126. Tran-Fadulu V, Pannu H, Kim DH, Vick GW III, Lonsford CM, Lafont AL et al. Analysis of multigenerational families with thoracic aortic aneurysms and dissections due to TGFBR1 or TGFBR2 mutations. J Med Genet 2009;46:607-13.
127. Pannu H, Fadulu VT, Chang J, Lafont A, Hasham SN, Sparks E et al. Mutations in transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms and dissections. Circulation 2005;112: 513-20.
128. Hasham SN, Willing MC, Guo DC, Muilenburg A, He R, Tran VT et al. Mapping a locus for familial thoracic aortic aneurysms and dissections (TAAD2) to 3p24-25. Circulation 2003;107:3184-90.
129. Lesauskaite V, Sinkunaite G, Benetis R, Grabauskas V, Vaskelyte J, Smalinskiene A et al. Matrix metalloproteinase-3 gene polymorphism and dilatative pathology of ascending thoracic aorta. Medicina (Kaunas) 2008;44:386-91.
130. Chen L, Wang X, Carter SA, Shen YH, Bartsch HR, Thompson RW et al. A single nucleotide polymorphism in the matrix metalloproteinase 9 gene (-8202A/G) is associated with thoracic aortic aneurysms and thoracic aortic dissection. J Thorac Cardiovasc Surg 2006;131:1045-52.
131. Foffa I, Festa PL, Ait-Ali L, Mazzone A, Bevilacqua S, Andreassi MG. Ascending aortic aneurysm in a patient with bicuspid aortic valve, positive history of systemic autoimmune diseases and common genetic factors: a case report. Cardiovasc Ultrasound 2009;7:34.
132. Hoyer J, Kraus C, Hammersen G, Geppert JP, Rauch A. Lethal cutis laxa with contractural arachnodactyly, overgrowth and soft tissue bleeding due to a novel homozygous fibulin-4 gene mutation. Clin Genet 2009; 76:276-81.
133. Small JV, Gimona M. The cytoskeleton of the vertebrate smooth muscle cell. Acta Physiol Scand 1998;164:341-8.
134. Renard M, Callewaert B, Baetens M, Campens L, Macdermot K, Fryns JP et al. Novel MYH11 and ACTA2 mutations reveal a role for enhanced TGFbeta signaling in FTAAD. Int J Cardiol 2011; 10.1016/j.ijcard. 2011.08.079.
135. Ersel M, Aksay E, Kiyan S, Bayraktaroglu S, Yuruktumen A, Ozsarac M et al. Can D-dimer testing help emergency department physicians to detect acute aortic dissections?. Anadolu Kardiyol Derg 2010;10:434-9.
136. Fan QK, Wang WW, Zhang ZL, Liu ZJ, Yang J, Zhao GS et al. Evaluation of D-dimer in the diagnosis of suspected aortic dissection. Clin Chem Lab Med 2010;48:1733-7.
137. Sakamoto K, Yamamoto Y, Okamatsu H, Okabe M. D-dimer is helpful for differentiating acute aortic dissection and acute pulmonary embolism from acute myocardial infarction. Hellenic J Cardiol 2011;52:123-7.
138. Weber T, Rammer M, Auer J, Maurer E, Aspock G, Eber B. Plasma concentrations of D-dimer predict mortality in acute type A aortic dissection. Heart 2006;92:836-7.
139. Wiegand J, Koller M, Bingisser R. Does a negative D-dimer test rule out aortic dissection?. Swiss Med Wkly 2007;137:462.
140. Ohlmann P, Hechler B, Cazenave JP, Gachet C. Measurement and manipulation of [Ca2+]i in suspensions of platelets and cell cultures. Methods Mol Biol 2004;273:229-50.